Key result
Calcium channel blockers are linked to lower fistula failure risk despite no effect on flow.
Why the study?
Do antihypertensive drugs (CCBs) affect arteriovenous fistula flow rates or failure in patients on maintenance hemodialysis?
Do antihypertensive drugs (CCBs) affect arteriovenous fistula flow rates or failure in patients on maintenance hemodialysis?
Answers are grounded in this paper and cite their sources.
Calcium channel blocker use in hemodialysis patients does not significantly alter AVF flow rates but may protect against AVF failure.
= 0.024), whereas vascular access type and duration were not significant. CCBs use was not associated with differences in AVF flow rate, however, its use may confer protection against AVF failure. Prospective studies are needed to confirm these findings and explore effects of antihypertensive classes on vascular access outcomes.
No takes yet. Share an insight, caveat, or question.
Elsayed et al. (2026) studied this question. Calcium channel blockers were not associated with differences in arteriovenous fistula flow rate but may protect against fistula failure in hemodialysis patients.
Synapse has enriched 10 related papers. Consider them for comparative context: